BIRC5 and acute lymphoblastic leukemia: Our identification of survivin expression in B-ALL [22] provides a new target for future therapeutic strategies that are already under investigation such as antisense inhibitors such as LY2181308, small molecule inhibitors such as YM-155, EM-1421, GDP366 and FL118, and siRNA.